Evaluation Of the Safety, Tolerability and Efficacy of Ranibizumab and Tocilizumab in Eyes With Diabetic Macular Edema

Trial Profile

Evaluation Of the Safety, Tolerability and Efficacy of Ranibizumab and Tocilizumab in Eyes With Diabetic Macular Edema

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Ranibizumab (Primary) ; Tocilizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms READ-4
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Apr 2017 Planned initiation date changed from 1 Feb 2016 to 1 Dec 2017.
    • 01 Dec 2015 Planned end date changed from 1 Oct 2017 to 1 Oct 2018, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top